From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Srdan Verstovsek, MD, PhD, from the MD Anderson Cancer Center, Houston, TX, notes the key biological and clinical characteristics that enable the earlier detection of AML. Monitoring symptoms of patients with characteristics such as anemia, low platelet count, and splenomegaly, would allow the early therapeutic intervention that could prevent the surprise of the more debilitating blastic phase in AML. Prof. Verstovsek strongly recommends following patients every 3-6 months for any changes in pattern of platelets and blasts to allow for the most effective treatment and improve chances of survival in patients.
The importance of quickly spotting the signs of AML
